United Historical Balance Sheet

UTHR Stock

USD 310.82 5.91 1.87%

Trend analysis of United Therapeutics balance sheet accounts such as Total Assets of 7.7 B, Short Long Term Debt Total of 295.3 M, Other Current Liabilities of 768.7 M or Total Current Liabilities of 775 M provides information on United Therapeutics' total assets, liabilities, and equity, which is the actual value of United Therapeutics to its prevalent stockholders. By breaking down trends over time using United Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining United Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether United Therapeutics is a good buy for the upcoming year.

United Therapeutics Inventory

165.79 Million

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.

About United Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of United Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. United Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of United Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which United currently owns. An asset can also be divided into two categories, current and non-current.

United Therapeutics Balance Sheet Chart

At this time, United Therapeutics' Cash is relatively stable compared to the past year. As of 03/27/2025, Non Current Assets Total is likely to grow to about 3.7 B, though Net Debt is likely to grow to (1.6 B).

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of United Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in United Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on United Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of United Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from United Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into United Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.At this time, United Therapeutics' Cash is relatively stable compared to the past year. As of 03/27/2025, Non Current Assets Total is likely to grow to about 3.7 B, though Net Debt is likely to grow to (1.6 B).

	2023	2024	2025 (projected)
Short and Long Term Debt Total	700M	300M	295.3M
Total Assets	7.2B	7.4B	7.7B

Short Long Term Debt Total Total Assets

United Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Good Will	Common Stock Total Equity	Short Term Investments	Property Plant And Equipment Gross	Short Term Debt	Intangible Assets
Total Assets		0.58	0.81	0.68	0.99	0.97	-0.54	0.98	-0.24	0.89	0.99	0.61	0.92	0.77	0.23	0.43	0.79	-0.55	0.65	0.99	0.78	0.45	0.94	0.98	0.83	0.49
Short Long Term Debt Total	0.58		0.18	0.16	0.51	0.49	0.28	0.49	-0.24	0.29	0.63	0.16	0.75	0.26	0.1	0.89	0.67	-0.24	0.9	0.52	0.75	0.42	0.64	0.46	0.63	0.43
Other Current Liab	0.81	0.18		0.52	0.84	0.82	-0.76	0.86	-0.09	0.86	0.78	0.68	0.67	0.78	0.16	0.13	0.52	-0.63	0.26	0.82	0.46	0.31	0.67	0.83	0.77	0.33
Total Current Liabilities	0.68	0.16	0.52		0.68	0.74	-0.58	0.64	-0.23	0.69	0.67	0.51	0.43	0.72	0.45	-0.14	0.49	-0.26	0.39	0.68	0.38	0.44	0.55	0.71	0.49	0.27
Total Stockholder Equity	0.99	0.51	0.84	0.68		0.97	-0.61	0.99	-0.24	0.91	0.98	0.62	0.9	0.77	0.2	0.35	0.77	-0.56	0.58	0.99	0.75	0.41	0.93	0.99	0.81	0.48
Property Plant And Equipment Net	0.97	0.49	0.82	0.74	0.97		-0.62	0.96	-0.17	0.91	0.96	0.68	0.86	0.8	0.35	0.33	0.72	-0.56	0.6	0.97	0.75	0.54	0.88	0.97	0.82	0.54
Net Debt	-0.54	0.28	-0.76	-0.58	-0.61	-0.62		-0.65	0.13	-0.83	-0.46	-0.69	-0.32	-0.68	-0.13	0.38	-0.28	0.58	0.13	-0.61	-0.14	-0.22	-0.33	-0.63	-0.3	-0.17
Retained Earnings	0.98	0.49	0.86	0.64	0.99	0.96	-0.65		-0.28	0.94	0.95	0.72	0.9	0.8	0.12	0.34	0.78	-0.69	0.55	0.98	0.75	0.41	0.89	0.96	0.77	0.54
Accounts Payable	-0.24	-0.24	-0.09	-0.23	-0.24	-0.17	0.13	-0.28		-0.27	-0.21	-0.16	-0.31	-0.23	0.4	-0.09	-0.36	0.34	-0.22	-0.27	-0.17	0.05	-0.23	-0.21	-0.01	0.04
Cash	0.89	0.29	0.86	0.69	0.91	0.91	-0.83	0.94	-0.27		0.84	0.79	0.77	0.85	0.19	0.14	0.66	-0.72	0.39	0.92	0.57	0.44	0.72	0.9	0.64	0.43
Non Current Assets Total	0.99	0.63	0.78	0.67	0.98	0.96	-0.46	0.95	-0.21	0.84		0.55	0.92	0.73	0.25	0.48	0.76	-0.49	0.7	0.96	0.8	0.45	0.94	0.96	0.86	0.51
Non Currrent Assets Other	0.61	0.16	0.68	0.51	0.62	0.68	-0.69	0.72	-0.16	0.79	0.55		0.54	0.82	0.12	0.08	0.52	-0.89	0.29	0.64	0.53	0.55	0.39	0.57	0.39	0.63
Cash And Short Term Investments	0.92	0.75	0.67	0.43	0.9	0.86	-0.32	0.9	-0.31	0.77	0.92	0.54		0.65	0.12	0.69	0.84	-0.58	0.77	0.91	0.83	0.45	0.92	0.87	0.78	0.47
Net Receivables	0.77	0.26	0.78	0.72	0.77	0.8	-0.68	0.8	-0.23	0.85	0.73	0.82	0.65		0.39	0.14	0.68	-0.64	0.47	0.79	0.51	0.63	0.58	0.77	0.58	0.29
Common Stock Shares Outstanding	0.23	0.1	0.16	0.45	0.2	0.35	-0.13	0.12	0.4	0.19	0.25	0.12	0.12	0.39		0.12	0.06	0.27	0.35	0.21	0.1	0.69	0.16	0.28	0.39	-0.06
Non Current Liabilities Total	0.43	0.89	0.13	-0.14	0.35	0.33	0.38	0.34	-0.09	0.14	0.48	0.08	0.69	0.14	0.12		0.51	-0.19	0.8	0.37	0.62	0.37	0.51	0.31	0.52	0.32
Other Current Assets	0.79	0.67	0.52	0.49	0.77	0.72	-0.28	0.78	-0.36	0.66	0.76	0.52	0.84	0.68	0.06	0.51		-0.55	0.76	0.81	0.79	0.52	0.8	0.73	0.58	0.38
Other Stockholder Equity	-0.55	-0.24	-0.63	-0.26	-0.56	-0.56	0.58	-0.69	0.34	-0.72	-0.49	-0.89	-0.58	-0.64	0.27	-0.19	-0.55		-0.23	-0.58	-0.52	-0.29	-0.36	-0.5	-0.31	-0.6
Total Liab	0.65	0.9	0.26	0.39	0.58	0.6	0.13	0.55	-0.22	0.39	0.7	0.29	0.77	0.47	0.35	0.8	0.76	-0.23		0.6	0.8	0.69	0.67	0.55	0.64	0.39
Total Current Assets	0.99	0.52	0.82	0.68	0.99	0.97	-0.61	0.98	-0.27	0.92	0.96	0.64	0.91	0.79	0.21	0.37	0.81	-0.58	0.6		0.75	0.44	0.93	0.98	0.79	0.47
Good Will	0.78	0.75	0.46	0.38	0.75	0.75	-0.14	0.75	-0.17	0.57	0.8	0.53	0.83	0.51	0.1	0.62	0.79	-0.52	0.8	0.75		0.6	0.79	0.7	0.65	0.71
Common Stock Total Equity	0.45	0.42	0.31	0.44	0.41	0.54	-0.22	0.41	0.05	0.44	0.45	0.55	0.45	0.63	0.69	0.37	0.52	-0.29	0.69	0.44	0.6		0.33	0.42	0.47	0.33
Short Term Investments	0.94	0.64	0.67	0.55	0.93	0.88	-0.33	0.89	-0.23	0.72	0.94	0.39	0.92	0.58	0.16	0.51	0.8	-0.36	0.67	0.93	0.79	0.33		0.91	0.8	0.44
Property Plant And Equipment Gross	0.98	0.46	0.83	0.71	0.99	0.97	-0.63	0.96	-0.21	0.9	0.96	0.57	0.87	0.77	0.28	0.31	0.73	-0.5	0.55	0.98	0.7	0.42	0.91		0.81	0.4
Short Term Debt	0.83	0.63	0.77	0.49	0.81	0.82	-0.3	0.77	-0.01	0.64	0.86	0.39	0.78	0.58	0.39	0.52	0.58	-0.31	0.64	0.79	0.65	0.47	0.8	0.81		0.37
Intangible Assets	0.49	0.43	0.33	0.27	0.48	0.54	-0.17	0.54	0.04	0.43	0.51	0.63	0.47	0.29	-0.06	0.32	0.38	-0.6	0.39	0.47	0.71	0.33	0.44	0.4	0.37

Click cells to compare fundamentals

United Therapeutics Account Relationship Matchups

United Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	4.6B	5.2B	6.0B	7.2B	7.4B	7.7B
Other Current Liab	319.2M	301.6M	339.1M	398.8M	732.1M	768.7M
Total Current Liabilities	323.3M	305.4M	343.2M	804.4M	738.1M	775.0M
Total Stockholder Equity	3.4B	4.0B	4.8B	6.0B	6.4B	6.8B
Property Plant And Equipment Net	731.6M	780.9M	861.5M	1.0B	1.2B	1.3B
Net Debt	61.3M	(94.8M)	(161.2M)	(507.7M)	(1.7B)	(1.6B)
Retained Earnings	3.8B	4.3B	5.0B	6.0B	7.2B	7.6B
Accounts Payable	9.9M	4.1M	3.8M	5.6M	6M	10.0M
Cash	738.7M	894.8M	961.2M	1.2B	1.7B	1.8B
Non Current Assets Total	2.4B	2.8B	2.7B	3.6B	3.5B	3.7B
Non Currrent Assets Other	169.9M	108.2M	114.3M	151.8M	222.1M	233.2M
Cash And Short Term Investments	3.0B	3.6B	4.2B	3.0B	3.3B	3.4B
Net Receivables	157.4M	198.7M	220.4M	278.9M	279.3M	293.3M
Common Stock Shares Outstanding	43.8M	44.6M	47.3M	48.5M	49.7M	50.8M
Liabilities And Stockholders Equity	4.6B	5.2B	6.0B	7.2B	7.4B	7.7B
Non Current Liabilities Total	896.5M	904.8M	904.6M	377.8M	181.9M	266.8M
Other Current Assets	88.3M	100.4M	219.2M	166.2M	169.7M	86.0M
Other Stockholder Equity	(430.5M)	(333.8M)	(190.8M)	(30.2M)	(775.6M)	(736.8M)
Total Liab	1.2B	1.2B	1.2B	1.2B	920M	563.3M
Total Current Assets	2.2B	2.3B	3.4B	3.6B	3.9B	4.1B
Short Term Investments	1.1B	1.0B	1.9B	1.8B	1.6B	1.6B
Property Plant And Equipment Gross	731M	1.1B	1.2B	1.5B	1.7B	1.8B
Intangible Assets	130.1M	16.6M	16.5M	80.5M	79.6M	83.6M
Other Liab	67M	79.4M	104.8M	76.8M	88.3M	60.5M
Other Assets	293.8M	1.6B	370.1M	413.5M	475.5M	284.7M
Inventory	86.5M	93.8M	102M	111.8M	157.9M	165.8M
Property Plant Equipment	738.5M	731.6M	780.9M	861.5M	990.7M	1.0B
Net Tangible Assets	2.6B	3.2B	3.9B	4.8B	5.5B	5.7B
Retained Earnings Total Equity	3.3B	3.8B	4.3B	5.0B	5.8B	6.1B

Pair Trading with United Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with United Stock

0.72

CDIOW

Cardio Diagnostics

Pair Corr

Moving against United Stock

0.58	LUCD	Lucid Diagnostics	Pair Corr
0.56	WM	Waste Management	Pair Corr
0.52	PG	Procter Gamble	Pair Corr
0.32	GE	GE Aerospace	Pair Corr

The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.

The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for United Stock Analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

United Historical Balance Sheet

United Therapeutics Inventory

165.79 Million

About United Balance Sheet Analysis

United Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

United Therapeutics balance sheet Correlations

United Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

United Therapeutics balance sheet Accounts

Pair Trading with United Therapeutics

Moving together with United Stock

Moving against United Stock

Additional Tools for United Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Retained Earnings	+ 0.99	Total Stockholder Equity
Total Current Assets	+ 0.99	Total Stockholder Equity
Property Plant And Equipment Gross	+ 0.99	Total Stockholder Equity

Other Stockholder Equity	- 0.89	Non Currrent Assets Other
Cash	- 0.83	Net Debt
Net Debt	- 0.76	Other Current Liab
Other Stockholder Equity	- 0.72	Cash
Other Stockholder Equity	- 0.69	Retained Earnings
Non Currrent Assets Other	- 0.69	Net Debt